These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19745644)

  • 1. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
    Haiman G; Pratt H; Miller A
    J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect.
    Haiman G; Pratt H; Miller A
    J Neurol Sci; 2008 Aug; 271(1-2):137-47. PubMed ID: 18504049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
    Miller A; Panitch H
    J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
    Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
    PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
    Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
    BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
    Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
    Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
    Rosen H
    Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
    Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
    Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies.
    Miller A
    J Neurol Sci; 2006 Jun; 245(1-2):153-9. PubMed ID: 16674978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
    Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
    J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
    Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
    Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
    Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
    CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.
    Miller A; Pratt H; Schiffer RB
    Expert Rev Neurother; 2011 Jul; 11(7):1077-88. PubMed ID: 21539437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Auditory event related potentials and source current density estimation in phonologic/auditory dyslexics.
    Moisescu-Yiflach T; Pratt H
    Clin Neurophysiol; 2005 Nov; 116(11):2632-47. PubMed ID: 16221569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
    Wahler RG; Reiman AT; Schrader JV
    J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudobulbar affect: an under-recognized and under-treated neurological disorder.
    Work SS; Colamonico JA; Bradley WG; Kaye RE
    Adv Ther; 2011 Jul; 28(7):586-601. PubMed ID: 21660634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.
    Pioro EP
    Neurol Ther; 2014 Jun; 3(1):15-28. PubMed ID: 26000221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orienting and maintenance of spatial attention in audition and vision: an event-related brain potential study.
    Salmi J; Rinne T; Degerman A; Alho K
    Eur J Neurosci; 2007 Jun; 25(12):3725-33. PubMed ID: 17610592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.